These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 19337010

  • 1. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes.
    Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S.
    J Endocrinol Invest; 2009 Jan; 32(1):23-7. PubMed ID: 19337010
    [Abstract] [Full Text] [Related]

  • 2. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I.
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [Abstract] [Full Text] [Related]

  • 3. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 4. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy.
    Jang HC, Lee SR, Vaz JA.
    Diabetes Obes Metab; 2009 Jan; 11(1):20-6. PubMed ID: 18479469
    [Abstract] [Full Text] [Related]

  • 5. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
    Ohira M, Endo K, Oyama T, Yamaguchi T, Ban N, Kawana H, Nagayama D, Nagumo A, Saiki A, Murano T, Watanabe H, Miyashita Y, Shirai K.
    Metabolism; 2011 Jan; 60(1):78-85. PubMed ID: 20667560
    [Abstract] [Full Text] [Related]

  • 6. Are insulin analogues an unavoidable necessity for the treatment of type 2 diabetes in developing countries? The case of Jordan.
    Hyassat D, Al Shekarchi N, Jaddou H, Liswi M, El-Khateeb M, Ajlouni KM.
    East Mediterr Health J; 2015 Dec 13; 21(10):729-35. PubMed ID: 26750163
    [Abstract] [Full Text] [Related]

  • 7. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
    El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.
    Diabetes Res Clin Pract; 2012 Dec 13; 98(3):408-13. PubMed ID: 23217267
    [Abstract] [Full Text] [Related]

  • 8. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.
    Chapman TM, Noble S, Goa KL.
    Treat Endocrinol; 2003 Dec 13; 2(1):71-6. PubMed ID: 15871555
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.
    Yang W, Ersoy C, Wang G, Ye S, Liu J, Miao H, Asirvatham A, Werther S, Kadu P, Chow F.
    Diabetes Res Clin Pract; 2019 Apr 13; 150():158-166. PubMed ID: 30872064
    [Abstract] [Full Text] [Related]

  • 10. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study.
    Sharma SK, Al-Mustafa M, Oh SJ, Azar ST, Shestakova M, Guler S, Vaz JA.
    Curr Med Res Opin; 2008 Mar 13; 24(3):645-52. PubMed ID: 18215338
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T.
    Clin Ther; 2007 May 13; 29(5):927-934. PubMed ID: 17697911
    [Abstract] [Full Text] [Related]

  • 12. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
    Chen JW, Lauritzen T, Bojesen A, Christiansen JS.
    Diabetes Obes Metab; 2006 Nov 13; 8(6):682-9. PubMed ID: 17026493
    [Abstract] [Full Text] [Related]

  • 13. Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes.
    Shi C, Sun L, Bai R, Wang H, Liu D, Du J.
    Curr Med Res Opin; 2019 Jun 13; 35(6):1091-1096. PubMed ID: 30550344
    [Abstract] [Full Text] [Related]

  • 14. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan 13; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 15. Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins.
    Walt JR, Loughran J, Fourlanos S, Barmanray RD, Zhu J, Varadarajan S, Kyi M.
    Intern Med J; 2024 Aug 13; 54(8):1329-1336. PubMed ID: 38578058
    [Abstract] [Full Text] [Related]

  • 16. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM, Noble S, Goa KL.
    Drugs; 2002 Aug 13; 62(13):1945-81. PubMed ID: 12215068
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Aug 13; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 18. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.
    Exp Clin Endocrinol Diabetes; 2006 Oct 13; 114(9):527-32. PubMed ID: 17115351
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan 13; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

  • 20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 13; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.